Funded Biotechnology Startups in Copenhagen
Copenhagen's biotechnology sector produced several notable financing events across the 24 rounds shown here, spanning May 2021 through November 2025.
Copenhagen's biotechnology sector produced several notable financing events across the 24 rounds shown here, spanning May 2021 through November 2025. The largest disclosed raise is Zealand Pharma's $1.0B round in June 2024, followed by Hemab's $157M Series C in November 2025 and ADCendo's $135M Series B in November 2024. Series A deals are the most frequently labeled stage in this set, with Antag Therapeutics ($84M, December 2024), Again ($43M, July 2024), and Enduro Genetics ($12M, February 2025) among the examples.
Late 2024 stands out for density: five rounds closed between October 29 and December 20, including ADCendo ($135M Series B), Antag Therapeutics ($84M Series A), IO Biotech ($60M), and Hervolution Therapeutics ($12M Series A). The dataset also captures non-dilutive mechanisms — SecondCircle received a $44M grant in August 2022 and Dianox received non-equity assistance in July 2022 — alongside a Post-IPO Equity raise from FluoGuide in March 2022, reflecting the breadth of financing structures active in this market.
Most recent rounds
24 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Zealand Pharma raised $1.0B in June 2024, making it the standout figure in this set. Hemab closed a $157M Series C in November 2025, and ADCendo raised $135M in a Series B in November 2024. Antag Therapeutics' $84M Series A in December 2024 ranks fourth among disclosed amounts.
Which funding stage appears most often among these Copenhagen biotech companies?
Series A is the most common labeled stage across the 24 rounds, with six examples including Antag Therapeutics ($84M), Again ($43M), Hervolution Therapeutics ($12M), Enduro Genetics ($12M), EvodiaBio ($7M), and Octarine Bio ($5M). Five additional rounds carry a Series Unknown designation, and three are classified as Seed.
How concentrated was Copenhagen biotech fundraising in late 2024?
Five rounds closed between October 29 and December 20, 2024: GLX Analytix (undisclosed), ADCendo ($135M Series B), Antag Therapeutics ($84M Series A), Hervolution Therapeutics ($12M Series A), and IO Biotech ($60M). That five-week window represents the densest cluster of activity in the entire dataset.
Which companies raised the most recent rounds?
The three newest rounds are Hemab's $157M Series C (November 2, 2025), SNIPR Biome's $41M Series B (August 7, 2025), and Evaxion Biotech's $80K round of unspecified type (June 3, 2025). Ousia Pharma and Neurescue both closed undisclosed rounds earlier in 2025.
What is the range of deal sizes visible in this segment?
Disclosed amounts span from $80K (Evaxion Biotech, June 2025) to $1.0B (Zealand Pharma, June 2024). Several companies — including Ousia Pharma, Neurescue, GLX Analytix, and Dianox — list no disclosed figure, so the distribution skews toward larger deals among the rounds with public amounts.
Are there any non-dilutive funding rounds present?
Yes. SecondCircle received a $44M grant in August 2022, and Dianox received non-equity assistance in July 2022. FluoGuide also appears with a Post-IPO Equity round in March 2022, indicating the dataset spans companies at a range of maturity and financing structures beyond standard venture rounds.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.